| R03AL04 |
Indacaterol and glycopyrronium bromide |
Ultibro Breezhaler |
Inhalation powder, hard capsule |
85 mcg /43 mcg |
|
30 x 1 capsules (unit dose) + 1 inhaler |
Novartis Europharm Limited, Ирландия |
1 |
UD (= 1 dose inhalation powder) |
- |
102.24 |
3.06324 |
91.9 |
75% |
68.92 |
|
J44.8 |
НСР-4636/15.09.2014; НСР-6138/29.04.2015.; НСР-11345/30.12.2016; Протокол 244/28.09.2017; НСР-14186/13.10.2017; НСР-15740/25.05.2018; НСР-16615/24.08.2018; НСР-17887/07.02.2019 |
02.04.2019 |
|
|
Активен |
3857 |
| R03AL05 |
Aclidinum bromide, Formoterol |
R03AL05 Aclidinum bromide, Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL05 |
Aclidinum bromide, Formoterol |
Brimica Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
AstraZeneca AB, Швеция |
2 |
UD |
- |
102.95 |
3.43167 |
102.95 |
75% |
77.21 |
|
J44.8 |
НСР-14441/17.11.2017 |
02.01.2018 |
|
|
Активен |
15934 |
| R03AL05 |
Aclidinum bromide, Formoterol |
Duaklir Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
AstraZeneca AB, Швеция |
2 |
UD |
- |
102.97 |
3.43167 |
102.95 |
75% |
77.21 |
|
J44.8 |
НСР-11253/16.12.2016 (допуска се предварително изпълнение); НСР-13783/12.09.2017 |
02.01.2018 |
|
|
Активен |
15519 |
| R03AL06 |
Tiotropium bromide, Olodaterol |
R03AL06 Tiotropium bromide, Olodaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL06 |
Tiotropium bromide, Olodaterol |
Spiolto Respimat |
Inhalation solution |
2,5 mcg/2,5 mcg |
|
Single pack: 1 cartridge, providing 60 puffs (30 medicinal doses) |
Boehringer Ingelheim International GmbH, Германия |
2 |
UD |
- |
92.76 |
3.092 |
92.76 |
75% |
69.57 |
|
J44.8 |
НСР-19823/20.09.2019 - Предварително изпълнение |
02.10.2019 |
|
|
Активен |
16702 |
| R03AL06 |
Tiotropium bromide, Olodaterol |
Spiolto Respimat |
Inhalation solution |
2,5 mcg/2,5 mcg |
|
1 Respimat reusable inhaler and 1 cartridge, providing 60 puffs (30 medicinal doses) |
Boehringer Ingelheim International GmbH, Германия |
2 |
UD |
- |
92.99 |
3.092 |
92.76 |
75% |
69.57 |
|
J44.8 |
НСР-11252/16.12.2016 г. (предварително изпълнение); НСР-13795/12.09.2017; НСР-15684/17.05.2018; НСР-17850/31.01.2019 предварително изпъленение; НСР-19597/21.08.2019; НСР-19215/12.07.2019 |
02.10.2019 |
|
|
Активен |
15523 |
| R03AL08 |
Fluticasone furoate, umeclidinium, vilanterol |
R03AL08 Fluticasone furoate, umeclidinium, vilanterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL08 |
Fluticasone furoate, umeclidinium, vilanterol |
Trelegy Ellipta |
Inhalation powder, pre dispensed |
92 mcg/55 mcg/22 mcg |
|
1 inhaler (30 doses) |
GlaxoSmithKline Trading Services Limited, Ирландия |
1 |
UD |
- |
137.72 |
4.13 |
123.9 |
75% |
92.93 |
|
J44.8 |
НСР-18448/11.04.2019 |
02.05.2019 |
|
|
Активен |
16495 |
| R03AL09 |
Formoterol, glycopyrronium bromide and beclomethasone |
R03AL09 Formoterol, glycopyrronium bromide and beclomethasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL09 |
Formoterol, glycopyrronium bromide and beclomethasone |
Trimbow |
Pressurised inhalation, solution |
87 mcg/5 mcg/9 mcg |
|
1 inhaler with 120 actuations |
Chiesi Farmaceutici SpA, Италия |
4 |
UD (=4 doses inhalaer) |
- |
137.72 |
4.59067 |
137.72 |
75% |
103.29 |
|
J44.8 |
НСР-20481/20.12.2019 Предварително изпълнение |
02.01.2020 |
|
|
Активен |
16827 |
| R03BA01 |
Beclometasone |
R03BA01 Beclometasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA01 |
Beclometasone |
Ecobec 100 MCG Easi-Breathe |
Pressurised inhalation, solution |
100 mcg/dose - 200 doses |
mcg |
1 |
Teva Czech Industries s.r.o., Чешка република |
1.5 |
mg |
26.57 |
- |
1.11911 |
14.92 |
100% |
14.92 |
|
J45.0,J45.1 |
№38/27.08.2009; НСР-1804/25.11.2013; НСР-4307/05.08.2014; НСР-5554/29.01.2015. |
16.02.2015 |
08.09.2012 |
|
Заличен |
3123 |
| R03BA01 |
Beclometasone |
Ecobec 250 MCG Easi-Breathe |
Pressurised inhalation, solution |
250 mcg/dose - 200 doses |
mcg |
1 |
Teva Czech Industries s.r.o., Чешка република |
1.5 |
mg |
37.3 |
- |
1.11911 |
37.3 |
100% |
37.3 |
|
J45.0,J45.1 |
№35/21.08.2009; НСР-5072/21.11.2014; НСР-7130/24.09.2015 |
16.10.2015 |
08.09.2012 |
|
Заличен |
3354 |
| R03BA02 |
Budesonide |
R03BA02 Budesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA02 |
Budesonide |
BUDIAIR JET |
Pressurised inhalation, solution |
0,2 mg/dose - 200 doses |
|
1 |
Chiesi Farmaceutici SpA, Италия |
1.5 |
mg |
22.04 |
- |
0.8264 |
22.04 |
100% |
22.04 |
|
J45.0,J45.1 |
КЦРР-475/19.04.2012 г.; НСР-3957/30.06.2014; НСР-11908/06.03.2017; НСР-13983/25.09.2017 |
02.11.2017 |
08.09.2012 |
|
Заличен |
2980 |
| R03BA02 |
Budesonide |
BUDIAIR MDI |
Pressurised inhalation, solution |
0,2 mg/dose - 200 doses |
mg |
1 |
Chiesi Farmaceutici SpA, Италия |
1.5 |
mg |
30.92 |
- |
1.1595 |
30.92 |
100% |
30.92 |
|
J45.0,J45.1 |
КЦРР-475/19.04.2012 г.; КЦРР-2342/21.02.2013. |
04.04.2013 |
08.09.2012 |
|
Заличен |
1186 |
| R03BA02 |
Budesonide |
R03BA02 Budesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA02 |
Budesonide |
Pulmicort |
Nebuliser suspension |
0.25 mg/ml-2 ml |
|
30 |
AstraZeneca AB, Швеция |
0.5 |
mg |
23.89 |
- |
0.79633 |
23.89 |
100% |
23.89 |
|
J45.0,J45.1 |
НСР-9469/ 09.06.2016; НСР-19559/21.08.2019 Предварително изпълнение |
02.09.2019 |
|
|
Активен |
15209 |
| R03BA02 |
Budesonide |
PULMICORT |
Nebuliser suspension |
0.25 mg/ml - 2 ml - 40 doses |
mg |
1 |
AstraZeneca AB, Швеция |
0.5 |
mg |
39.61 |
- |
0.99025 |
39.61 |
100% |
39.61 |
|
J45.0,J45.1 |
НСР-4545/22.08.2014.; НСР-7578/26.11.2015. и КП-13/29.01.2016.; НСР-9516/09.06.2016 |
02.07.2016 |
|
|
Заличен |
3145 |
| R03BA02 |
Budesonide |
PULMICORT |
Nebuliser suspension |
0.25 mg/ml - 2 ml - 20 doses |
mg |
1 |
AstraZeneca AB, Швеция |
0.5 |
mg |
27.82 |
- |
1.391 |
27.82 |
100% |
27.82 |
|
J45.0,J45.1 |
№ 34/21,08,2009 г.; КЦРР-763/07.06.2012 г.; НСР-3442/30.04.2014; Протокол 81/28.08.2014; НСР-5442/16.01.2015. |
16.02.2015 |
08.09.2012 |
16.11.2013 |
Заличен |
2769 |
| R03BA02 |
Budesonide |
R03BA02 Budesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA02 |
Budesonide |
Pulmicort Turbuhaler |
Inhalation powder |
200 micrograms/dose (100 doses) |
mg |
1 |
AstraZeneca AB, Швеция |
0.8 |
mg |
14.98 |
- |
0.5992 |
14.98 |
100% |
14.98 |
|
J45.0,J45.1 |
НСР-2120/14.12.2013; НСР-12384/18.04.2017 |
02.06.2017 |
|
|
Активен |
2353 |
| R03BA05 |
Fluticasone propionate |
R03BA05 Fluticasone propionate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA05 |
Fluticasone |
Arquist |
Pressurised inhalation, suspension |
250 mcg/dose - 120 doses |
mcg |
1 |
Cipla Europe NV, Белгия |
1.5 |
mg |
29.88 |
- |
1.494 |
29.88 |
100% |
29.88 |
|
J44.8,J45.0,J45.1 |
НСР-14170/13.10.2017; НСР-17524/13.12.2018; НСР-19755/04.09.2019 |
02.10.2019 |
|
|
Активен |
15903 |